KUALA LUMPUR, MALAYSIA – Media OutReach – 25 May 2023 – Cancer is a leading cause of death globally. Nevertheless, early identification of the disease has been linked to lower mortality rates, with the survival rate at one and five years for most cancers being higher if the cancer is detected at the first stage and treated early.
Malaysia, as a Cancer Care Center of Excellence in the region, is a top-of-mind destination among healthcare travellers. This is due, in part, to the country’s commitment to cutting-edge cancer screening and treatment capabilities as well as its quality patient care and service.
According to Dr. Aqilah Othman, Consultant Clinical Oncologist at Sunway Medical Centre, cancer screening allows doctors to detect any abnormal growth or lumps in the body. “These may be benign or at a precancerous stage. The removal of these lesions can reduce the risk of them transforming into cancer,” she added.
Alongside a better prognosis, early cancer detection may reduce the need for more intrusive and aggressive therapies. For instance, a tiny and localized tumor may require less invasive treatments or less extensive surgeries, leading to a lower risk of complications and faster recovery. Early detection of the disease could also lessen the need for systemic treatments with possibly more harmful side effects or for prolonged radiation therapy.
Malaysia stands at the forefront in implementing advanced and modern cancer screening tools in order to optimize the treatment quality and patient care. Sunway Medical Center is equipped with a Digital Positron Emission Tomography/Computed Tomography (PET/CT) scanner, for one.
“A Digital PET/CT scanner can support higher quality imaging, which helps nuclear medicine physicians to detect even the tiniest lesions in a patient’s body. On top of that, we also use the M2PK Stool test, which is a visual immunochromatographic rapid test that is used to detect the M2-pyruvate kinase (M2-PK) enzyme in stool samples for colorectal cancer screening,” shared Dr. Heng Siew Peng, General Manager of the Cancer Center at Sunway Medical Center.
Malaysia is also home to a first-in-Asia Mediso AnyScan hybrid imaging system. Located in Thomson Hospital Kota Damansara, this hybrid imaging system is capable of carrying out all contemporary nuclear medicine operations, including both PET and single-photon emission computed tomography (SPECT) imaging. The machine integrates the characteristics of these two imaging modalities into a single device, providing for a wide range of diagnostic capabilities. This gives medical practitioners extensive information on their patients’ functional and anatomical characteristics as well as assisting in diagnosis and therapy planning.
With top-notch cancer screening tools, Malaysia is able to provide patients with more accurate and precise cancer diagnoses. The location, size and metabolic activity of tumors can all be precisely determined with advanced and modern imaging technologies. This aids medical professionals in developing action plans that can precisely target cancerous cells or particular molecular networks that drive the development and spread of cancer. Understanding a tumour’s molecular profile allows medical professionals to choose the most targeted therapy, improving the likelihood of successful treatment while minimizing harm to healthy tissues.
The majority of private hospitals in Malaysia are set up to provide screening, diagnosis, treatment and follow-up care for all cancer-related treatments in one convenient location. Therefore, those who travel for healthcare and need cancer treatment have a lot of discretion in selecting the facility that best suits their needs. Additionally, they are also assured of prompt care and treatment because there is typically little to no waiting time for an appointment.
For more information on Malaysia Healthcare and its services, please visit
https://malaysiahealthcare.org.my or visit our social feeds at:
www.facebook.com/MHTCMalaysia or at LinkedIn (Malaysia Healthcare Travel Council).
Hashtag: #MalaysiaHealthcare
The issuer is solely responsible for the content of this announcement.
